Investors

Investors2019-12-08T19:36:42+00:00

Overview

CanaQuest Medical Corp is a life science company focused on medical cannabis products. The Company is committed to developing novel health products that utilize cannabis, hemp, and botanical extracts, including algae oils.

The Company has engaged two prestigious Canadian universities to research and develop formulated products, which the company is in the process of launching. Our research is focused on the use of cannabis in the context of cancer and the use of cannabis derivatives for the development of our novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”.

CanaQuest was awarded a cannabis sales-import-export license from Health Canada. Additionally, CanaQuest filed an international patent on a game-changing discovery, Mentabinol®, protecting THC users from negative psychiatric side-effects. Recently the Company won the Go Global Awards “Business of the Year – Category of Life Science”, presented by the International Trade Council.

Presentations

CanaQuest won the Go Global Awards “Business of the Year – Category of Life Science”, presented by the International Trade Council.

Health Europa Articles

Impacting Lives on Global Scale
CanaQuest Delivers on Passion
Patent Filing for THC formulation

Links

OTC Markets (OTC: CANQF)
OTC Filings
Related Video on Addiction
CBD Research Video
Audio Interview
CEOCFO Magazine Interview
Mentabinol Delivers Minus the Trip
Success Story in Life Sciences Ontario

Licensed Producers Canada Articles

Global Expansion Plans
A New Cannabis Formulation

Strategic Partnerships

Partners and Collaborators

  • Supply, processing, packaging and distribution
  • Medical clinics and health care practitioners
  • E-commerce
  • Canada, USA and Globally

View additional information on the Partners Page

Focus Areas

Our strategic focus is on the development of proprietary research to develop safe novel health products that utilize cannabis, hemp, and botanical extracts, while blocking the negative psychiatric side-effects. Our research is focused on the use of cannabis derivatives for the development of our novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. Positive data from CanaQuest’s research and pre-clinical trials has positioned the Company to bring its first THC & CBD based products to market.

As well, we are focusing on formulations for pain management as an alternative to opioids, which will have clinical implications for a host of other ailments, such as nausea, glaucoma, multiple sclerosis, osteoarthritis.

News & Press

1109, 2019

CanaQuest Medical Corp Announces Award of a Cannabis Purchase/Sales Licence as Permitted under the Health Canada Cannabis Act, through its Wholly Owned Subsidiary, ADC BioMedical Corp.

September 11th, 2019|0 Comments

Licence is a foundation for the company to begin domestic and international sales of our Proprietary Cannabis and Botanical formulated products. Under the proposed Health Canada Amendment for Cannabis Edibles Regulations, our products will [...]

Collaboration Partners

Licensed Producers: We have engaged in several discussions with major Licensed Producers/Distributors to sell medicinal cannabis domestically and internationally. As well, these companies are reviewing the strength of our IP to potentially facilitate the processing and distribution of our formulations because our formulated products do not compete with their product lines.

Licensed Processor/Pharmaceutical Company: We have engaged in several discussions with a major pharmaceutical company, international distributor and GMP manufacturer who has provided highly positive feedback of the approach Dr. Laviolette has adopted in his research and pre-clinical animal trials, the depth of research and the effective integration of the various research departments at Western University. We believe we can leverage their expertise with multiple formulations, delivery systems for improved bioavailability, including by integrating our formulation into soft gels and tablets for timed release of the formulations. We would also expect to take advantage of their supply, processing and distribution capabilities and collaborate further on R & D and human trials for our formulations.

We have reviewed our strategy and believe it is more efficient to partner with existing Licensed Producers who have facilities compliant with good manufacturing practices (GMP) necessary for the preparation of our formulations. Additionally, we are seeking our own purchase/sales, import/export license without possession under the Cannabis Act to distribute formulations and develop our brand as permitted under the Cannabis Act Regulations. We have included a full description of the cannabis-related licensing process at the end of this Business Description section for further information and disclosure. We do not require similar special licensing with respect to algae related sales.